Pulmonary Embolism: An Update Based on the Revised AWMF-S2k Guideline

Christian F. Opitz,F. Joachim Meyer

DOI: https://doi.org/10.1055/s-0044-1779011

2024-05-01

Hämostaseologie

Abstract:Pulmonary embolism (PE) is the third most common acute cardiovascular disease. The risk of PE increases with age and mortality is high. Patients are stratified into hemodynamically stable versus unstable patients, as this has important implications for diagnosis and therapy. Since clinical signs and symptoms of acute PE are nonspecific, the clinical likelihood of PE is estimated to guide diagnostic pathways. D-dimer testing is performed in hemodynamically stable patients with low or intermediate probability of PE and the visualization of thromboembolism and its sequelae is commonly achieved with computed tomography pulmonary angiography (CTPA), supplemented by ultrasound techniques. With confirmed PE, another risk stratification estimates disease severity and defines intensity and setting of the ensuing treatment. The therapeutic spectrum ranges from outpatient treatment with initial oral anticoagulation to thrombolytic or interventional treatment in the intensive care unit or catheterization laboratory. In single cases, even acute surgical thrombectomy is attempted. Received: 17 September 2023 Accepted: 14 December 2023 Article published online: 30 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

hematology

What problem does this paper attempt to address?

This paper attempts to address the issues of diagnosis, risk stratification, and treatment of Pulmonary Embolism (PE). Specifically:

1. **Diagnosis Issues**:
- The paper discusses the clinical manifestations of PE, which are often non-specific, including sudden onset of dyspnea, chest pain, syncope, or near-syncope.
- It emphasizes the assessment of the likelihood of PE through history, risk factors, and clinical findings when PE is suspected.
- It introduces the application of D-dimer testing in patients with low or moderate probability of PE, with a negative predictive value of over 95%, which can avoid unnecessary imaging tests.
- It describes in detail the use of computed tomography pulmonary angiography (CTPA) as the primary imaging modality, with a sensitivity and specificity of 94% and 98%, respectively.
- It mentions the important role of echocardiography in the diagnosis of acute PE, especially for immediate ultrasound examination (POCUS) in hemodynamically unstable patients.

2. **Risk Stratification Issues**:
- The paper proposes categorizing PE patients into hemodynamically stable and unstable groups, which is significant for diagnosis and treatment.
- It uses the simplified Pulmonary Embolism Severity Index (sPESI) for prognostic scoring, considering factors such as age, comorbidities, and clinical presentation.
- It further stratifies intermediate-risk patients based on the level of right ventricular dysfunction and cardiac biomarkers into intermediate-high risk and intermediate-low risk.

3. **Treatment Issues**:
- For high-risk patients who are hemodynamically unstable, urgent reperfusion therapy (such as systemic thrombolysis) is the primary goal.
- Hemodynamically stable PE patients require anticoagulation therapy based on risk stratification, ranging from outpatient treatment to inpatient treatment.
- It discusses the selection of different treatment methods, including systemic thrombolysis, catheter-directed thrombolysis, mechanical thrombectomy, and surgical embolectomy.
- It specifically mentions treatment considerations for special patient groups (such as pregnant women and cancer patients).

Overall, this paper aims to update the PE diagnosis and treatment strategies based on the revised AWMF-S2k guidelines, emphasizing the importance of early recognition, accurate diagnosis, and individualized treatment.